{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:51:00Z","timestamp":1761519060415,"version":"3.40.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40265-013-0067-6","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T08:16:12Z","timestamp":1370333772000},"page":"907-918","source":"Crossref","is-referenced-by-count":3,"title":["Recent Developments in Drug Therapy for Cushing\u2019s Disease"],"prefix":"10.1007","volume":"73","author":[{"given":"Rob","family":"van der Pas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo J.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,5]]},"reference":[{"issue":"3","key":"67_CR1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","volume":"96","author":"RN Clayton","year":"2011","unstructured":"Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing\u2019s disease over 50\u00a0years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96(3):632\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"67_CR2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jc.2006-2112","volume":"92","author":"OM Dekkers","year":"2007","unstructured":"Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, et al. Mortality in patients treated for Cushing\u2019s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92(3):976\u201381.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"67_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/jc.86.1.117","volume":"86","author":"J Lindholm","year":"2001","unstructured":"Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing\u2019s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9258","key":"67_CR4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(00)04172-6","volume":"357","author":"M Boscaro","year":"2001","unstructured":"Boscaro M, Barzon L, Fallo F, Sonino N. Cushing\u2019s syndrome. Lancet. 2001;357(9258):783\u201391.","journal-title":"Lancet"},{"issue":"9522","key":"67_CR5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing\u2019s syndrome. Lancet. 2006;367(9522):1605\u201317.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"67_CR6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000314317","volume":"92","author":"AM Pereira","year":"2010","unstructured":"Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing\u2019s syndrome. Neuroendocrinology. 2010;92(Suppl 1):65\u201370.","journal-title":"Neuroendocrinology"},{"issue":"10","key":"67_CR7","doi-asserted-by":"crossref","first-page":"E129","DOI":"10.1210\/jc.2010-0512","volume":"95","author":"J Tiemensma","year":"2010","unstructured":"Tiemensma J, Biermasz NR, Middelkoop HA, van der Mast RC, Romijn JA, Pereira AM. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing\u2019s disease. J Clin Endocrinol Metab. 2010;95(10):E129\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"67_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/B:PITU.0000004798.27230.ed","volume":"6","author":"MD Johnson","year":"2003","unstructured":"Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary. 2003;6(2):81\u20137.","journal-title":"Pituitary"},{"issue":"5","key":"67_CR9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","volume":"158","author":"SM Webb","year":"2008","unstructured":"Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, et al. Evaluation of health-related quality of life in patients with Cushing\u2019s syndrome with a new questionnaire. Eur J Endocrinol. 2008;158(5):623\u201330.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"67_CR10","first-page":"279","volume":"7","author":"NA Tritos","year":"2011","unstructured":"Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev. 2011;7(5):279\u201389.","journal-title":"Nat Rev"},{"issue":"5","key":"67_CR11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2005.02380.x","volume":"63","author":"AB Atkinson","year":"2005","unstructured":"Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing\u2019s disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63(5):549\u201359.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"67_CR12","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"67_CR13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2265.2007.03028.x","volume":"68","author":"KR Mullan","year":"2008","unstructured":"Mullan KR, Atkinson AB. Endocrine clinical update: where are we in the therapeutic management of pituitary-dependent hypercortisolism? Clin Endocrinol (Oxf). 2008;68(3):327\u201337.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"67_CR14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2265.2002.01511.x","volume":"56","author":"DA Rees","year":"2002","unstructured":"Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing\u2019s disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002;56(4):541\u201351.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"67_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1210\/jc.2005-1204","volume":"91","author":"F Esposito","year":"2006","unstructured":"Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing\u2019s disease. J Clin Endocrinol Metab. 2006;91(1):7\u201313.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"67_CR16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3171\/jns.1994.80.1.0037","volume":"80","author":"Z Ram","year":"1994","unstructured":"Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH. Early repeat surgery for persistent Cushing\u2019s disease. J Neurosurg. 1994;80(1):37\u201345.","journal-title":"J Neurosurg"},{"key":"67_CR17","doi-asserted-by":"crossref","unstructured":"Vance ML. Pituitary radiotherapy. Endocrinology and metabolism clinics of North America. 2005;34(2):479\u201387, xi.","DOI":"10.1016\/j.ecl.2005.01.005"},{"issue":"2","key":"67_CR18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1210\/jc.2007-1220","volume":"93","author":"JH Petit","year":"2008","unstructured":"Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab. 2008;93(2):393\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5\u20136","key":"67_CR19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000083476","volume":"82","author":"JK Devin","year":"2004","unstructured":"Devin JK, Allen GS, Cmelak AJ, Duggan DM, Blevins LS. The efficacy of linear accelerator radiosurgery in the management of patients with Cushing\u2019s disease. Stereotact Funct Neurosurg. 2004;82(5\u20136):254\u201362.","journal-title":"Stereotact Funct Neurosurg"},{"issue":"3","key":"67_CR20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJM199701163360303","volume":"336","author":"J Estrada","year":"1997","unstructured":"Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing\u2019s disease. N Engl J Med. 1997;336(3):172\u20137.","journal-title":"N Engl J Med"},{"key":"67_CR21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1749-6632.2002.tb04418.x","volume":"970","author":"D Morris","year":"2002","unstructured":"Morris D, Grossman A. The medical management of Cushing\u2019s syndrome. Ann N Y Acad Sci. 2002;970:119\u201333.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"67_CR22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311\u201326.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"67_CR23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2008-2101","volume":"94","author":"C Bruin de","year":"2009","unstructured":"de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94(4):1118\u201324.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"67_CR24","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89(5):2452\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"67_CR25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur J Endocrinol. 2010;163(5):709\u201316.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"67_CR26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, et al. The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"67_CR27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura ESL, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary. 2010;13(2):123\u20139.","journal-title":"Pituitary"},{"issue":"1","key":"67_CR28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"67_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med. 2007;356(1):39\u201346.","journal-title":"N Engl J Med"},{"key":"67_CR30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2265.2011.04326.x","volume":"77","author":"V Delgado","year":"2012","unstructured":"Delgado V, Biermasz NR, van Thiel SW, Ewe SH, Ajmone Marsan N, Holman ER, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012;77:99\u2013105.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"67_CR31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157\u201398.","journal-title":"Front Neuroendocrinol"},{"issue":"11","key":"67_CR32","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91(11):4482\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"67_CR33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152(4):645\u201354.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"67_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clpt.2005.04.003","volume":"78","author":"P Ma","year":"2005","unstructured":"Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther. 2005;78(1):69\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"67_CR35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707\u201316.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"67_CR36","first-page":"E278","volume":"289","author":"J Hoek van der","year":"2005","unstructured":"van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol. 2005;289(2):E278\u201387.","journal-title":"Am J Physiol"},{"issue":"1","key":"67_CR37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, et al. Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115\u201322.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"67_CR38","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med. 2012;366(10):914\u201324.","journal-title":"N Engl J Med"},{"issue":"19","key":"67_CR39","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med. 2010;362(19):1846\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"67_CR40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.diabet.2012.10.005","volume":"39","author":"Y Reznik","year":"2013","unstructured":"Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, et al. Management of hyperglycaemia in Cushing\u2019s disease: experts\u2019 proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34\u201341.","journal-title":"Diabetes Metab"},{"issue":"4","key":"67_CR41","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","volume":"93","author":"D Ferone","year":"2008","unstructured":"Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008;93(4):1412\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"67_CR42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1530\/acta.0.1200760","volume":"120","author":"SW Lamberts","year":"1989","unstructured":"Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201\u2013995 on ACTH secretion in Nelson\u2019s syndrome and Cushing\u2019s disease. Acta Endocrinol. 1989;120(6):760\u20136.","journal-title":"Acta Endocrinol"},{"issue":"2","key":"67_CR43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","volume":"130","author":"GK Stalla","year":"1994","unstructured":"Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J, et al. Octreotide exerts different effects in vivo and in vitro in Cushing\u2019s disease. Eur J Endocrinol. 1994;130(2):125\u201331.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"67_CR44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1210\/endo-110-4-1147","volume":"110","author":"A Schonbrunn","year":"1982","unstructured":"Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology. 1982;110(4):1147\u201354.","journal-title":"Endocrinology"},{"issue":"1","key":"67_CR45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1677\/JME-08-0110","volume":"42","author":"C Bruin de","year":"2009","unstructured":"de Bruin C, Feelders RA, Waaijers AM, van Koetsveld PM, Sprij-Mooij DM, Lamberts SW, et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol. 2009;42(1):47\u201356.","journal-title":"J Mol Endocrinol"},{"issue":"11","key":"67_CR46","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/en.136.11.5070","volume":"136","author":"Y Xu","year":"1995","unstructured":"Xu Y, Berelowitz M, Bruno JF. Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology. 1995;136(11):5070\u20135.","journal-title":"Endocrinology"},{"issue":"3","key":"67_CR47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000072798","volume":"78","author":"S Park","year":"2003","unstructured":"Park S, Kamegai J, Kineman RD. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1\u2013sst5) mRNA levels: evidence for direct and somatostatin-mediated effects. Neuroendocrinology. 2003;78(3):163\u201375.","journal-title":"Neuroendocrinology"},{"key":"67_CR48","unstructured":"Feelders RA, De Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, et al. Medical treatment of Cushing\u2019s disease with pasireotide mono- or combination therapy with cabergoline and ketoconazole modulates somatostatin receptor subtype expression on corticotroph tumor cells. Endocrine Abstracts OR 146; 2010."},{"issue":"8","key":"67_CR49","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1210\/jc.81.8.2885","volume":"81","author":"F Vignati","year":"1996","unstructured":"Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J Clin Endocrinol Metab. 1996;81(8):2885\u201390.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"67_CR50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11102-010-0264-1","volume":"14","author":"TH Dillard","year":"2011","unstructured":"Dillard TH, Gultekin SH, Delashaw JB Jr, Yedinak CG, Neuwelt EA, Fleseriu M. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary. 2011;14(1):80\u201391.","journal-title":"Pituitary"},{"key":"67_CR51","doi-asserted-by":"crossref","unstructured":"Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery. 2009;64(4):E773\u20134 (discussion E4).","DOI":"10.1227\/01.NEU.0000339115.12803.4E"},{"issue":"10","key":"67_CR52","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4592\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"67_CR53","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1100\/tsw.2010.210","volume":"10","author":"L Curto","year":"2010","unstructured":"Curto L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, et al. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing\u2019s disease\u2014report of a case and literature review. Sci World J. 2010;10:2132\u20138.","journal-title":"Sci World J"},{"issue":"10","key":"67_CR54","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1365-2362.2011.02520.x","volume":"41","author":"AI McCormack","year":"2011","unstructured":"McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Investig. 2011;41(10):1133\u201348.","journal-title":"Eur J Clin Investig"},{"issue":"8","key":"67_CR55","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","volume":"108","author":"M Paez-Pereda","year":"2001","unstructured":"Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Investig. 2001;108(8):1123\u201331.","journal-title":"J Clin Investig"},{"issue":"9","key":"67_CR56","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","volume":"147","author":"V Castillo","year":"2006","unstructured":"Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, et al. Retinoic acid as a novel medical therapy for Cushing\u2019s disease in dogs. Endocrinology. 2006;147(9):4438\u201344.","journal-title":"Endocrinology"},{"issue":"10","key":"67_CR57","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","volume":"97","author":"F Pecori Giraldi","year":"2012","unstructured":"Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, et al. Potential role for retinoic acid in patients with Cushing\u2019s disease. J Clin Endocrinol Metab. 2012;97(10):3577\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"67_CR58","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Investig. 2011;121(12):4712\u201321.","journal-title":"J Clin Investig"},{"issue":"6","key":"67_CR59","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1210\/jcem-63-6-1365","volume":"63","author":"P Loli","year":"1986","unstructured":"Loli P, Berselli ME, Tagliaferri M. Use of ketoconazole in the treatment of Cushing\u2019s syndrome. J Clin Endocrinol Metab. 1986;63(6):1365\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"67_CR60","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM198709243171307","volume":"317","author":"N Sonino","year":"1987","unstructured":"Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987;317(13):812\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"67_CR61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","volume":"35","author":"N Sonino","year":"1991","unstructured":"Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing\u2019s syndrome: experience in 34 patients. Clin Endocrinol (Oxf). 1991;35(4):347\u201352.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"67_CR62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","volume":"158","author":"F Castinetti","year":"2008","unstructured":"Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease. Eur J Endocrinol. 2008;158(1):91\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"67_CR63","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0022-3565(25)22688-X","volume":"240","author":"SW Lamberts","year":"1987","unstructured":"Lamberts SW, Bons EG, Bruining HA, de Jong FH. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther. 1987;240(1):259\u201364.","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"67_CR64","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF01733014","volume":"63","author":"D Engelhardt","year":"1985","unstructured":"Engelhardt D, Dorr G, Jaspers C, Knorr D. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klinische Wochenschrift. 1985;63(13):607\u201312.","journal-title":"Klinische Wochenschrift"},{"issue":"6","key":"67_CR65","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/0002-9343(88)90312-9","volume":"84","author":"AP Farwell","year":"1988","unstructured":"Farwell AP, Devlin JT, Stewart JA. Total suppression of cortisol excretion by ketoconazole in the therapy of the ectopic adrenocorticotropic hormone syndrome. Am J Med. 1988;84(6):1063\u20136.","journal-title":"Am J Med"},{"issue":"5","key":"67_CR66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2265.1987.tb01189.x","volume":"27","author":"DR McCance","year":"1987","unstructured":"McCance DR, Hadden DR, Kennedy L, Sheridan B, Atkinson AB. Clinical experience with ketoconazole as a therapy for patients with Cushing\u2019s syndrome. Clin Endocrinol (Oxf). 1987;27(5):593\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"67_CR67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199401273300407","volume":"330","author":"JA Como","year":"1994","unstructured":"Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994;330(4):263\u201372.","journal-title":"N Engl J Med"},{"issue":"2","key":"67_CR68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1022308429992","volume":"5","author":"LK Nieman","year":"2002","unstructured":"Nieman LK. Medical therapy of Cushing\u2019s disease. Pituitary. 2002;5(2):77\u201382.","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"67_CR69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000314292","volume":"92","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing\u2019s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology. 2010;92(Suppl 1):111\u20135.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"67_CR70","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1210\/endo-122-2-618","volume":"122","author":"GK Stalla","year":"1988","unstructured":"Stalla GK, Stalla J, Huber M, Loeffler JP, Hollt V, von Werder K, et al. Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology. 1988;122(2):618\u201323.","journal-title":"Endocrinology"},{"issue":"1","key":"67_CR71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1677\/joe.0.1080037","volume":"108","author":"JM Burrin","year":"1986","unstructured":"Burrin JM, Yeo TH, Ashby MJ, Bloom SR. Effect of ketoconazole on adrenocorticotrophic hormone secretion in vitro and in vivo. J Endocrinol. 1986;108(1):37\u201341.","journal-title":"J Endocrinol"},{"issue":"10","key":"67_CR72","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF03350926","volume":"11","author":"M Terzolo","year":"1988","unstructured":"Terzolo M, Panarelli M, Piovesan A, Torta M, Paccotti P, Angeli A. Ketoconazole treatment in Cushing\u2019s disease. Effect on the circadian profile of plasma ACTH and cortisol. J Endocrinol Investig. 1988;11(10):717\u201321.","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"67_CR73","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/00003246-200103000-00039","volume":"29","author":"MJ DeLeon","year":"2001","unstructured":"DeLeon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Crit Care Med. 2001;29(3):668\u201370.","journal-title":"Crit Care Med"},{"issue":"4","key":"67_CR74","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ajh.1063","volume":"66","author":"S Shibata","year":"2001","unstructured":"Shibata S, Kami M, Kanda Y, Machida U, Iwata H, Kishi Y, et al. Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide. Am J Hematol. 2001;66(4):303\u20135.","journal-title":"Am J Hematol"},{"issue":"4","key":"67_CR75","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1530\/eje.1.02120","volume":"154","author":"M Riedl","year":"2006","unstructured":"Riedl M, Maier C, Zettinig G, Nowotny P, Schima W, Luger A. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol. 2006;154(4):519\u201324.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"67_CR76","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1530\/JOE-12-0310","volume":"215","author":"R Pas van der","year":"2012","unstructured":"van der Pas R, Hofland LJ, Hofland J, Taylor AE, Arlt W, Steenbergen J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012;215(3):403\u201312.","journal-title":"J Endocrinol"},{"issue":"2","key":"67_CR77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","volume":"35","author":"JA Verhelst","year":"1991","unstructured":"Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing\u2019s syndrome. Clin Endocrinol (Oxf). 1991;35(2):169\u201378.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"67_CR78","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio.574","volume":"7","author":"M Fassnacht","year":"2011","unstructured":"Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician\u2019s update. Nat Rev. 2011;7(6):323\u201335.","journal-title":"Nat Rev"},{"issue":"27","key":"67_CR79","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","volume":"27","author":"I Veytsman","year":"2009","unstructured":"Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27(27):4619\u201329.","journal-title":"J Clin Oncol"},{"issue":"6","key":"67_CR80","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0022-4731(73)90033-2","volume":"4","author":"RB Young","year":"1973","unstructured":"Young RB, Bryson MJ, Sweat ML, Street JC. Complexing of DDT and o, p\u2019DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem. 1973;4(6):585\u201391.","journal-title":"J Steroid Biochem"},{"issue":"5","key":"67_CR81","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-92-5-613","volume":"92","author":"DE Schteingart","year":"1980","unstructured":"Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing\u2019s disease with mitotane and pituitary irradiation. Ann Int Med. 1980;92(5):613\u20139.","journal-title":"Ann Int Med"},{"issue":"9","key":"67_CR82","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenicky","year":"2011","unstructured":"Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2011;96(9):2796\u2013804.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"67_CR83","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM197903013000903","volume":"300","author":"JP Luton","year":"1979","unstructured":"Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D, et al. Treatment of Cushing\u2019s disease by O, p\u2019DDD. Survey of 62 cases. N Engl J Med. 1979;300(9):459\u201364.","journal-title":"N Engl J Med"},{"issue":"4","key":"67_CR84","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","volume":"167","author":"C Baudry","year":"2012","unstructured":"Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, et al. Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center. Eur J Endocrinol. 2012;167(4):473\u201381.","journal-title":"Eur J Endocrinol"},{"issue":"9182","key":"67_CR85","first-page":"951","volume":"354","author":"S Kawai","year":"1999","unstructured":"Kawai S, Ichikawa Y, Kaburaki J, Yoshida T. 18 years mitotane therapy for intractable Cushing\u2019s disease. Lancet. 1999;354(9182):951.","journal-title":"Lancet"},{"issue":"2","key":"67_CR86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","volume":"23","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res. 2009;23(2):273\u201389.","journal-title":"Best Pract Res"},{"issue":"8350","key":"67_CR87","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(83)90710-9","volume":"2","author":"B Allolio","year":"1983","unstructured":"Allolio B, Stuttmann R, Fischer H, Leonhard W, Winkelmann W. Long-term etomidate and adrenocortical suppression. Lancet. 1983;2(8350):626.","journal-title":"Lancet"},{"issue":"6408","key":"67_CR88","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1136\/bmj.287.6408.1835","volume":"287","author":"IW Fellows","year":"1983","unstructured":"Fellows IW, Bastow MD, Byrne AJ, Allison SP. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed). 1983;287(6408):1835\u20137.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"4","key":"67_CR89","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1517\/14728210903413522","volume":"14","author":"DE Schteingart","year":"2009","unstructured":"Schteingart DE. Drugs in the medical treatment of Cushing\u2019s syndrome. Expert Opin Emerg Drugs. 2009;14(4):661\u201371.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"9","key":"67_CR90","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1210\/jc.86.9.4104","volume":"86","author":"J Krakoff","year":"2001","unstructured":"Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2001;86(9):4104\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"67_CR91","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","volume":"70","author":"HM Schulte","year":"1990","unstructured":"Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing\u2019s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab. 1990;70(5):1426\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"67_CR92","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0274","volume":"167","author":"VA Preda","year":"2012","unstructured":"Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review. Eur J Endocrinol. 2012;167(2):137\u201343.","journal-title":"Eur J Endocrinol"},{"key":"67_CR93","unstructured":"Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, et al. Patients with Cushing\u2019s disease achieve normal urinary cortisol with LCI699, a potent 11\u03b2-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study. Endocrine Abstracts OR012; 2012."},{"issue":"6","key":"67_CR94","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","volume":"160","author":"F Castinetti","year":"2009","unstructured":"Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, et al. Merits and pitfalls of mifepristone in Cushing\u2019s syndrome. Eur J Endocrinol. 2009;160(6):1003\u201310.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"67_CR95","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039\u201349.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"67_CR96","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.cellsig.2007.07.007","volume":"19","author":"A Baragli","year":"2007","unstructured":"Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal. 2007;19(11):2304\u201316.","journal-title":"Cell Signal"},{"issue":"5463","key":"67_CR97","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","volume":"288","author":"M Rocheville","year":"2000","unstructured":"Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science (New York, NY). 2000;288(5463):154\u20137.","journal-title":"Science (New York, NY)"},{"issue":"6","key":"67_CR98","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","volume":"95","author":"S Petersenn","year":"2010","unstructured":"Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6):2781\u20139.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0067-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0067-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0067-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T11:47:42Z","timestamp":1746013662000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0067-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":98,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0067-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"type":"print","value":"0012-6667"},{"type":"electronic","value":"1179-1950"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}